The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study

被引：0
|
作者：
Watanabe, Takuya
Nakayama, Goro
Ishigure, Kiyoshi
Hayashi, Naomi
Yaguchi, Toyohisa
Kojima, Hiroshi
Tsuboi, Kenji
Ito, Akihiro
Deguchi, Tomohiro
Sekiya, Masanori
Tanaka, Chie
Ando, Yuichi
Ohashi, Norifumi
Kodera, Yasuhiro
机构：
[1] Komaki City Hosp, Komaki, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Nagoya, Aichi 4648601, Japan
[3] Konan Kosei Hosp, Konan, Aichi, Japan
[4] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan
[5] Kainan Hosp, Yayomi, Japan
[6] Aichi Canc Ctr Hosp, Okazaki, Aichi, Japan
[7] Tosei Hosp, Seto, Japan
[8] Toki City Hosp, Toki, Gifu, Japan
[9] Tajimi Prefectual Hosp, Tajimi, Japan
[10] Nakatsugawa City Hosp, Nakatsugawa, Japan
[11] Nagoya Grad Sch Med, Nagoya, Aichi, Japan
[12] Nagoya Univ Hosp, Nagoya, Aichi, Japan
[13] Aichi Med Univ, Nagakute, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
564
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: Final report of CCOG-0902 study.
    Hayashi, Naomi
    Nakayama, Goro
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Yaguchi, Toyohisa
    Kojima, Hiroshi
    Tsuboi, Kenji
    Ito, Akihiro
    Deguchi, Tomohiro
    Sekiya, Masanori
    Tanaka, Chie
    Uehara, Keisuke
    Ando, Yuichi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] The efficacy and safety of CapeOX plus bevacizumab therapy with a planned oxaliplatin stop-and-go strategy in patients with metastatic colorectal cancer: A multicenter, single-arm, phase II study (CCOG-0902 study).
    Sunakawa, Yuuki
    Nakayama, Goro
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Uehara, Keisuke
    Kanda, Mitsuro
    Murotani, Kenta
    Fujii, Tsutomu
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [5] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [6] A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
    Yutaka Ogata
    Mototsugu Shimokawa
    Takaho Tanaka
    Yasunori Emi
    Eiji Oki
    Hiroshi Saeki
    Noriaki Sadanaga
    Tetsuya Kusumoto
    Tetsuo Touyama
    Masami Kimura
    Hideo Baba
    Yoshito Akagi
    Kazuo Shirouzu
    Yoshihiko Maehara
    International Journal of Clinical Oncology, 2016, 21 : 335 - 343
  • [7] A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
    Ogata, Yutaka
    Shimokawa, Mototsugu
    Tanaka, Takaho
    Emi, Yasunori
    Oki, Eiji
    Saeki, Hiroshi
    Sadanaga, Noriaki
    Kusumoto, Tetsuya
    Touyama, Tetsuo
    Kimura, Masami
    Baba, Hideo
    Akagi, Yoshito
    Shirouzu, Kazuo
    Maehara, Yoshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (02) : 335 - 343
  • [8] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [9] (XELOX) capecitabine plus oxaliplatin: Clinical efficacy and safety in the first-line treatment for metastatic gastric cancer
    Manuguerra, G.
    Alu, M.
    Leonardi, V.
    Laudani, A.
    Palmisano, V.
    Pepe, A.
    Arcuri, C.
    Savio, G.
    Cusimano, M.
    Calabria, C.
    Porretto, C.
    de Bella, M. Tamburo
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 5 - 5
  • [10] (Xelox) capecitabina plus oxaliplatin: Clinical efficacy and safety in the first-line treatment for metastatic gastric cancer
    Alu, M.
    Leonardi, V
    Laudani, A.
    Palmisano, V
    Tamburo De Bella, M.
    Rondello, G.
    Manuguerra, G.
    Porretto, C.
    Tartaglia, L.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : VII52 - VII53
12345